Status:
UNKNOWN
Non Randomized Comparative Study With Control
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Allogeneic Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
NK cells are lymphocytes who play a role in the control of viral infections , tumor and fœtal tolerance. They belong to innate immune cells but they have a link with adaptative immunity. Indeed, after...
Detailed Description
For both groups: 28ml of peripheral blood samples are collected at different points. Group 1 : before and after anti viral treatment . Control group 2: one point after allo-HSCT; Control group 3: 1 po...
Eligibility Criteria
Inclusion
- patients who reactivate CMV or AdV after allogeneic HSCT ;
- Age\>18 years; indication for a antiviral treatment:
- at least 1 PCR CMV\>1000 copies/ml or 1 PCR ADV\>1000 copies/ml or at least 2 ADV PCR positive - sites (stools, throat, urines);
- signed informed consent;
- Control group: allogeneic HSC transplanted patients;
- Age\>18 years; no CMV or AdV reactivation ;
- signed informed consent;
- Healthy donors group: HSC donor;
- Age\>18 years;
- signed informed consent
Exclusion
- none
Key Trial Info
Start Date :
September 27 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03294824
Start Date
September 27 2013
End Date
June 1 2018
Last Update
May 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Pitié Salpêtriere
Paris, France, 75651